Sugi Predict

Sugi Predict / Targets / PXMP4

PXMP4

Peroxisomal membrane protein 4 · Q9Y6I8 · PXMP4 on Sugi Atlas →

0 patent compounds predicted against PXMP4, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to PXMP4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone. PHASE4COMPLETED
Betaine and Peroxisome Biogenesis Disorders PHASE3COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
RCDP Natural History Study nanUNKNOWN
the Role of plin5 in the Development of Nonalcoholic Fatty Liver Disease. nanUNKNOWN
Investigating the Genetic Basis of Pseudoexfoliation Syndrome, Angle-closure Glaucoma and Primary Open-angle Glaucoma nanRECRUITING
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Molecular Mechanisms of Exercise Benefits to Insulin Resistant People nanCOMPLETED
Fatty Acid Binding Proteins and Markers of Cellular Senescence in Cancer Survivors nanNOT_YET_RECRUITING
Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases nanCOMPLETED
OEA for Targeting Lipid Metabolism in GWI nanCOMPLETED
Vitreous Proteomics of Patients Suffering From Pseudoexfoliation Syndrome nanACTIVE_NOT_RECRUITING
Familial Partial Lipodystrophy Study nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
Plasma Levels of Matrix Metalloproteinases (MMPs) and Degree of DNA Fragmentation in Pseudoexfoliation (PEX) Glaucoma nanCOMPLETED
Immune Cell Response to Stimuli nanRECRUITING
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. nanCOMPLETED
Evaluation of Risk of hEpatocellular Carcinoma nanRECRUITING
Fatty Acid Metabolism and Insulin Sensitivity: the Role of Endurance Exercise nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Open-Label Study of Omega 3 Oil Supplementation for Aging-Related Cognitive Decline nanCOMPLETED
What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum nanCOMPLETED
Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease nanUNKNOWN
Epidemiology of Atherosclerosis nanCOMPLETED
Susceptibility Genes in Autism Spectrum Disorders nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED
Study of Protein Translocation in Patients With Beta-Oxidation Disorders nanCOMPLETED
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PXMP4 binder may also engage these)

ProteinNameSimilarity
Q9JJW0 — 1.000 Q9JJW0 →
A5PJL1 — 0.997 A5PJL1 →
P59382 — 0.996 P59382 →
Q6GQ39 — 0.970 Q6GQ39 →
Q5U4F4 — 0.968 Q5U4F4 →
Q3ZBE6 — 0.966 Q3ZBE6 →
Q9CYV5 — 0.964 Q9CYV5 →
Q86UB9 — 0.958 Q86UB9 →
Q99MS3 — 0.951 Q99MS3 →
Q6NYK8 — 0.951 Q6NYK8 →
Q3ZBX1 — 0.948 Q3ZBX1 →
Q8R2R1 — 0.948 Q8R2R1 →
SOAT2 Sterol O-acyltransferase 2 0.948 landscape →
Q9Y6A1 — 0.948 Q9Y6A1 →
Q4QRH7 — 0.947 Q4QRH7 →
Q96HR9 — 0.947 Q96HR9 →
Q29036 — 0.947 Q29036 →
Q9BZW4 — 0.947 Q9BZW4 →
Q5PQQ4 — 0.947 Q5PQQ4 →
Q9CXR4 — 0.946 Q9CXR4 →
Q2QL34 — 0.946 Q2QL34 →
F1QF89 — 0.946 F1QF89 →
Q3KQE5 — 0.946 Q3KQE5 →
Q8K2A8 — 0.946 Q8K2A8 →
Q641S2 — 0.946 Q641S2 →
Q96HA9 — 0.946 Q96HA9 →
Q99PR0 — 0.946 Q99PR0 →
F4I8Q7 — 0.945 F4I8Q7 →
Q1L9A2 — 0.945 Q1L9A2 →
Q9ZRA3 — 0.945 Q9ZRA3 →